Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine vs ropivacaine periarticular injection in unicompartmental knee arthroplasty
ChiCTR2400088414Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupivacaine in postoperative pain (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Pain at rest and during movement at 24 hours postoperatively. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2400088414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088414.